RESUMEN
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and causes severe cardiac and brain damage, leading to behavioral alterations in humans and animals. However, the mechanisms involved in memory impairment during T. cruzi infection remain unknown. It has long been recognized that the enzymatic activities of acetylcholinesterase (AChE) and Na+, K+-ATPase are linked with memory dysfunction during other trypanosomiasis. Thus, the aim of this study was to evaluate the involvement of cerebral AChE and Na+, K+-ATPase activities in the memory impairment during T. cruzi (Colombian strain) infection. A significant decrease on latency time during the inhibitory avoidance task was observed in animals infected by T. cruzi compared to uninfected animals, findings compatible to memory dysfunction. Moreover, the cerebral AChE activity increased, while the Na+, K+-ATPase decreased in T. cruzi infected compared to uninfected animals. Histopathology revealed mild to moderate multifocal gliosis in the cerebral cortex and light focal meningeal lymphoplasmacytic infiltrate, which may have contributed to memory loss. Based on these evidences, we can conclude that T. cruzi (Colombian strain) causes memory impairment in mice experimentally infected. Moreover, the changes in AChE and Na+, K+-ATPase activities may be considered a mechanism involved in disease pathogenesis.
Asunto(s)
Acetilcolinesterasa/metabolismo , Infecciones Protozoarias del Sistema Nervioso Central/enzimología , Corteza Cerebral/enzimología , Trastornos de la Memoria/enzimología , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Trypanosoma cruzi/patogenicidad , Animales , Conducta Animal , Encéfalo/enzimología , Encéfalo/parasitología , Encéfalo/patología , Infecciones Protozoarias del Sistema Nervioso Central/parasitología , Infecciones Protozoarias del Sistema Nervioso Central/patología , Infecciones Protozoarias del Sistema Nervioso Central/psicología , Corteza Cerebral/parasitología , Corteza Cerebral/patología , Enfermedad de Chagas , Modelos Animales de Enfermedad , Femenino , Gliosis/enzimología , Gliosis/parasitología , Gliosis/patología , Corazón , Humanos , Trastornos de la Memoria/parasitología , Trastornos de la Memoria/patología , Trastornos de la Memoria/psicología , Ratones , Tripanosomiasis/parasitología , Tripanosomiasis/psicologíaRESUMEN
Glutaryl-CoA dehydrogenase deficiency or glutaric acidemia type I (GA I) is an inherited neurometabolic disorder biochemically characterized by tissue accumulation of predominantly glutaric (GA) and 3-hydroxyglutaric (3OHGA) acids and clinically by severe neurological symptoms and structural brain abnormalities, manifested as progressive cerebral atrophy and acute striatum degeneration following encephalopathic crises, whose pathophysiology is still in debate. Considering that reactive astrogliosis is a common finding in brain of GA I patients, in the present study we investigated the effects of GA and 3OHGA on glial activity determined by S100B release by rat C6-glioma cells. We also evaluated the effects of these organic acids on some parameters of oxidative stress in these astroglial cells. We observed that GA and 3OHGA significantly increased S100B secretion and thiobarbituric acid-reactive substances (lipid peroxidation), whereas GA markedly decreased reduced glutathione levels in these glioma cells. This is the first report demonstrating that the major metabolites accumulating in GA I activate S100B secretion in astroglial cells, indicating activation of these cells. We also showed that GA and 3OHGA induced oxidative stress in C6 lineage cells, confirming previous findings observed in brain fresh tissue. It is therefore presumed that reactive glial cells and oxidative damage may underlie at least in part the neuropathology of GA I.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/metabolismo , Astrocitos/metabolismo , Encefalopatías Metabólicas/metabolismo , Glutaratos/metabolismo , Glutaril-CoA Deshidrogenasa/deficiencia , Factores de Crecimiento Nervioso/metabolismo , Proteínas S100/metabolismo , Errores Innatos del Metabolismo de los Aminoácidos/enzimología , Errores Innatos del Metabolismo de los Aminoácidos/patología , Animales , Astrocitos/patología , Atrofia , Encefalopatías Metabólicas/enzimología , Encefalopatías Metabólicas/patología , Línea Celular Tumoral , Cuerpo Estriado/enzimología , Cuerpo Estriado/metabolismo , Cuerpo Estriado/patología , Gliosis/enzimología , Gliosis/metabolismo , Gliosis/patología , Glutaratos/farmacología , Glutatión/antagonistas & inhibidores , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/fisiología , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Ratas , Subunidad beta de la Proteína de Unión al Calcio S100 , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismoRESUMEN
Acetylcholinesterase (AChE) activities in CNS physiopathology are increasingly diverse and range from neuritogenesis, through synaptogenesis, to enhancement of amyloid fiber assembly. In Alzheimer's disease, senile plaques and neurodegeneration specially affect regions enriched for cholinergic synapses. In this study we show an effect of AChE that could contribute to the increased deposition of Abeta in certain regions. Affinity-purified AChE induced the expression of amyloid-beta-precursor protein (beta-APP) in glial cells in a concentration-dependent manner up to 5 nM. In glia, AChE also increased inducible nitric oxide synthase (iNOS) assessed by immunocytochemistry and decreased reductive metabolism as evidence of cell activation. AChE could increase the expression of beta-APP in astrocytes and microglia as result of the activation of glial cells. As a whole, we found that AChE has additional effects that could result in an increased synthesis of Abeta, both by increasing beta-APP expression of astrocytes and by further activating glial cells.